Motoki Takamuro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Motoki Takamuro has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Shota Muraji
Department of Cardiology Fukuoka Children's Hospital Fukuoka Japan
2 shared publications Aki Mori
National Cerebral and Cardiovascular Center
1 shared publication- Aya Miyazaki
Department of Paediatric Cardiology, Department of Adult Congenital Heart Disease, Seirei Hamamatsu General Hospital , Hamamatsu
1 shared publication Ayako Okada
Department of Cardiovascular Medicine Shinshu University School of Medicine Nagano Japan
1 shared publication- Daisuke Kawano
Department of Cardiology Saitama Medical University International Medical Center Hidaka Saitama Japan
1 shared publication Eiki Nishihara
Department of Pediatric Cardiology and Neonatology Ogaki Municipal Hospital Gifu Japan
1 shared publication
Latest Publications
- Open Access
- 13 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Midterm Efficacy of SubcutAneous Implantable CardioVErter ‐Defibrillator in ≤ 18 Year‐Old CHILDREN ( SAVE CHILDREN ‐ II Registry)
Background: The subcutaneous implantable cardioverter‐defibrillator (S‐ICD) avoids transvenous leads and is a promising option for sudden cardiac death (SCD) prevention in pediatric patients. However, mid‐term outcomes and post‐shock management strategies remain insufficiently characterized. Methods: This multicenter, retrospective observational study included pediatric patients (≤ 18 years) who underwent S‐ICD implantation between February 2016 and July 2021. Clinical characteristics, pre‐implant screening, procedural details, device‐related events, and follow‐up data were analyzed. The incidence and management of appropriate and inappropriate therapies and subsequent recurrence were evaluated. Results: Ninety‐six patients (median age 14.5 years) were enrolled and followed for a median of 70 months (29–75.0 months). Sensing vector suitability remained stable despite somatic growth. Appropriate shocks occurred in 32 patients (33.7%), while inappropriate shocks occurred in 27 (28.4%). After appropriate therapy, intensified pharmacological treatment and catheter ablation prevented recurrent device therapy in 45.5% and 50.0% of cases, respectively, although device shock occurred in 50.9% despite intervention. Following inappropriate therapy, device reprogramming and lifestyle guidance prevented recurrence in 71.4% of patients (15/21). Device‐related infection was rare (2 cases), and no lead fractures were observed. Conclusions: S‐ICD therapy demonstrated favorable mid‐term safety and efficacy in pediatric patients, with durable sensing performance and a low incidence of device‐related infection. Although inappropriate shocks were not uncommon, appropriate post‐shock management effectively reduced recurrence, supporting S‐ICD as a viable option for selected pediatric patients without pacing requirements.
- 13 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Open AccessMidterm Efficacy of SubcutAneous Implantable CardioVErter ‐Defibrillator in ≤ 18 Year‐Old CHILDREN ( SAVE CHILDREN ‐ II Registry)
Background: The subcutaneous implantable cardioverter‐defibrillator (S‐ICD) avoids transvenous leads and is a promising option for sudden cardiac death (SCD) prevention in pediatric patients. However, mid‐term outcomes and post‐shock management strategies remain insufficiently characterized. Methods: This multicenter, retrospective observational study included pediatric patients (≤ 18 years) who underwent S‐ICD implantation between February 2016 and July 2021. Clinical characteristics, pre‐implant screening, procedural details, device‐related events, and follow‐up data were analyzed. The incidence and management of appropriate and inappropriate therapies and subsequent recurrence were evaluated. Results: Ninety‐six patients (median age 14.5 years) were enrolled and followed for a median of 70 months (29–75.0 months). Sensing vector suitability remained stable despite somatic growth. Appropriate shocks occurred in 32 patients (33.7%), while inappropriate shocks occurred in 27 (28.4%). After appropriate therapy, intensified pharmacological treatment and catheter ablation prevented recurrent device therapy in 45.5% and 50.0% of cases, respectively, although device shock occurred in 50.9% despite intervention. Following inappropriate therapy, device reprogramming and lifestyle guidance prevented recurrence in 71.4% of patients (15/21). Device‐related infection was rare (2 cases), and no lead fractures were observed. Conclusions: S‐ICD therapy demonstrated favorable mid‐term safety and efficacy in pediatric patients, with durable sensing performance and a low incidence of device‐related infection. Although inappropriate shocks were not uncommon, appropriate post‐shock management effectively reduced recurrence, supporting S‐ICD as a viable option for selected pediatric patients without pacing requirements.
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e044374
Unplanned Hospitalization Due to All‐Cause Morbidity and Its Real‐World Management Practices in Patients With Fontan Circulation
Background: Management strategies of unplanned hospitalizations (UPH) vary and have not been well characterized in patients with Fontan circulation. Methods: We prospectively followed 3226 Fontan patients for 3 years to characterize the current UPH status and elucidate the associations between in‐hospital management strategies and postdischarge outcomes. Results: A total of 243 UPHs occurred (2.5 cases/100 person‐years). Fontan‐related UPHs accounted for 154 cases (63%), most commonly due to heart failure (19%), protein‐losing enteropathy (16%), hemorrhage (14%), arrhythmia (9%), thromboembolism (3%), and plastic bronchitis (2%). Fontan‐unrelated UPHs (89 cases; 37%) were mainly due to infections (19%). Adult patients were more frequently hospitalized for hemorrhage and thromboembolism ( P P <0.01–0.001). Conclusions: We clarified real‐world practices related to UPHs in Fontan patients. Specific in‐hospital treatment strategies were associated with the risk of readmission. Further studies are warranted to determine the causal relationships between treatment approaches and outcomes for standardized management strategies.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e044374
Open AccessUnplanned Hospitalization Due to All‐Cause Morbidity and Its Real‐World Management Practices in Patients With Fontan Circulation
Background: Management strategies of unplanned hospitalizations (UPH) vary and have not been well characterized in patients with Fontan circulation. Methods: We prospectively followed 3226 Fontan patients for 3 years to characterize the current UPH status and elucidate the associations between in‐hospital management strategies and postdischarge outcomes. Results: A total of 243 UPHs occurred (2.5 cases/100 person‐years). Fontan‐related UPHs accounted for 154 cases (63%), most commonly due to heart failure (19%), protein‐losing enteropathy (16%), hemorrhage (14%), arrhythmia (9%), thromboembolism (3%), and plastic bronchitis (2%). Fontan‐unrelated UPHs (89 cases; 37%) were mainly due to infections (19%). Adult patients were more frequently hospitalized for hemorrhage and thromboembolism ( P P <0.01–0.001). Conclusions: We clarified real‐world practices related to UPHs in Fontan patients. Specific in‐hospital treatment strategies were associated with the risk of readmission. Further studies are warranted to determine the causal relationships between treatment approaches and outcomes for standardized management strategies.